Spectrum of mast cell activation disorders
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Mast cell (MC) activation disorders present with multiple symptoms including flushing, pruritus, hypotension, gastrointestinal complaints, irritability, headaches, concentration/memory loss and neuropsychiatric issues. These disorders are classified as: cutaneous and systemic mastocytosis with a c-kit mutation and clonal MC activation disorder, allergies, urticarias and inflammatory disorders and mast cell activation syndrome (MCAS), idiopathic urticaria and angioedema. MCs are activated by IgE, but also by cytokines, environmental, food, infectious, drug and stress triggers, leading to secretion of multiple mediators. The symptom profile and comorbidities associated with these disorders, such as chronic fatigue syndrome and fibromyalgia, are confusing. We propose the use of the term 'spectrum' and highlight the main symptoms, useful diagnostic tests and treatment approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Valent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin‐Nelemans, H. C., Hamdy, N. A. T., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01807.x · Cited by 750 · cited 4×
“4 ng/ml or greater than the upper limit of normal; in patients with previous hypotensive episodes and/or syncope; urticaria pigmentosa (UP) present in adult patients; unexplained or explained anaphylaxis provoked with hymenoptera sting even when specific IgE testing to hymenoptera is negative [46,48,49], indicating th…”
BackgroundInfluentialValent, P., Akin, C., Arock, M., Brockow, K., Butterfield, J. H., Carter, M. C., Castells, M., Escribano, L., Hartmann, K., Lieberman, P., et al. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000328760 · Cited by 654
Diagnostic Value of Tryptase in Anaphylaxis and Mastocytosis
Schwartz, L. B. (2006) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2006.05.010 · Cited by 477 · cited 1×
“of serum tryptase is available, then a rapid increase is considered as a reliable index; if there is not, then the baseline has to be assessed after the patient’s complete recovery or during a symptom-free interval at least 24–48 h after complete resolution of all symptoms [38–40].”
BackgroundBonadonna, P., Perbellini, O., Passalacqua, G., Caruso, B., Colarossi, S., Dal Fior, D., Castellani, L., Bonetto, C., Frattini, F., Dama, A., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.11.018 · Cited by 392 · cited 2×
“A typical example is the presence of an allergy against hymenoptera venom(s) in patients suffering from mastocytosis [22–25].”
BackgroundMast cell activation syndrome: Proposed diagnostic criteria
Akin, C., Valent, P., & Metcalfe, D. D. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.08.035 · Cited by 327
Lin, R. Y., Schwartz, L. B., Curry, A., Pesola, G. R., Knight, R. J., Lee, H.-S., Bakalchuk, L., Tenenbaum, C., & Westfal, R. E. (2000) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2000.107600 · Cited by 277 · cited 1×
“of serum tryptase is available, then a rapid increase is considered as a reliable index; if there is not, then the baseline has to be assessed after the patient’s complete recovery or during a symptom-free interval at least 24–48 h after complete resolution of all symptoms [38–40].”
BackgroundAkin, C., Scott, L. M., Kocabas, C. N., Kushnir-Sukhov, N., Brittain, E., Noel, P., & Metcalfe, D. D. (2007) · Blood · doi:10.1182/blood-2006-06-028100 · Cited by 240 · cited 1×
“Anaphylaxis may be different in patients with IA and in patients with indolent SM because urticaria is absent during anaphylactic episodes and serum tryptase levels are significantly elevated, while in patients with IA, urticaria is present in higher frequency and serum IgE is significantly elevated [54].”
BackgroundAlvarez-Twose, I., González-de-Olano, D., Sánchez-Muñoz, L., Matito, A., Jara-Acevedo, M., Teodosio, C., García-Montero, A., Morgado, J. M., Orfao, A., & Escribano, L. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000329856 · Cited by 184
Recombinant allergens promote expression of CD203c on basophils in sensitized individuals
Hauswirth, A. W., Natter, S., Ghannadan, M., Majlesi, Y., Schernthaner, G.-H., Sperr, W. R., Bühring, H.-J., Valenta, R., & Valent, P. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.125257 · Cited by 169 · cited 1×
“Various assays have been proposed to document MC and basophil activation [30,31].”
BackgroundÁlvarez-Twose, I., Zanotti, R., González-de-Olano, D., Bonadonna, P., Vega, A., Matito, A., Sánchez-Muñoz, L., Morgado, J. M., Perbellini, O., García-Montero, A., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.06.020 · Cited by 142 · cited 1×
“Therefore, these cases may be misinterpreted as just presenting an allergic condition with no further investigation being indicated to rule out an associated mastocytosis, which in turn is a well-known risk factor for adverse reactions to venom immunotherapy [50]; presence of unexplained osteoporosis, hepatomegaly, sp…”
BackgroundMast cell activation syndrome: A newly recognized disorder with systemic clinical manifestations
Hamilton, M. J., Hornick, J. L., Akin, C., Castells, M. C., & Greenberger, N. J. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.04.037 · Cited by 132 · cited 9×
“In conclusion, while the symptoms of MC mediators are present in all of the primary MCADs, the features below appear specifically: multifocal MC aggregates and possible UP only in patients with SM; D816V KIT mutation and aberrant CD25 expression on BM MC in patients with SM, MMAS; baseline tryptase and baseline 24-h u…”
BackgroundInfluentialSonneck, K., Florian, S., Müllauer, L., Wimazal, F., Födinger, M., Sperr, W. R., & Valent, P. (2007) · International Archives of Allergy and Immunology · doi:10.1159/000096442 · Cited by 129 · cited 1×
“4 ng/ml or greater than the upper limit of normal; in patients with previous hypotensive episodes and/or syncope; urticaria pigmentosa (UP) present in adult patients; unexplained or explained anaphylaxis provoked with hymenoptera sting even when specific IgE testing to hymenoptera is negative [46,48,49], indicating th…”
BackgroundZhang, B., Asadi, S., Weng, Z., Sismanopoulos, N., & Theoharides, T. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049767 · Cited by 121 · cited 1×
“We recently showed that activated MC secreted mitochondrial components extracellularly, and these acted as ‘autopathogens’ triggering autoinflammatory responses [9,10].”
BackgroundSelf-citationExpression of α-tryptase and β-tryptase by human basophils
Jogie-Brahim, S., Min, H.-K., Fukuoka, Y., Xia, H.-Z., & Schwartz, L. B. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.02.032 · Cited by 113
Familial Occurrence of Systemic Mast Cell Activation Disease
Molderings, G. J., Haenisch, B., Bogdanow, M., Fimmers, R., & Nöthen, M. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076241 · Cited by 94 · cited 1×
“Family history is of great importance because the prevalence of MCAD is higher among relatives of MCAD patients than would be expected by chance [34].”
BackgroundMast Cells in Allergic and Inflammatory Diseases
Sismanopoulos, N., Delivanis, D.-A., Alysandratos, K.-D., Angelidou, A., Therianou, A., Kalogeromitros, D., & C. Theoharides, T. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212800165997 · Cited by 87 · cited 1×
“MCs are activated primarily by IgEdependent mechanism (allergen, anti-IgE) and also by IgE-independent mechanism (IgG, bacterial and viral components, complement fragments [C3a, C5a]) cytokines, chemokines, drugs, physical stimuli and hormones [2,4].”
BackgroundButterfield, J. H., & Weiler, C. R. (2008) · International Archives of Allergy and Immunology · doi:10.1159/000144042 · Cited by 81
Awad, J. A., Morrow, J. D., & Roberts, L. J. (1994) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(94)90371-9 · Cited by 66 · cited 1×
“Serum PGD2 may be useful, but cannot be considered as a valid marker because its release can come from cellular elements through processing of peripheral blood samples due to a diet rich in niacin or niacin products used for atherosclerosis [42] and there are no proposed criteria for its minimal physiological increase.”
BackgroundSamorapoompichit, P., Kiener, H. P., Schernthaner, G.-H., Jordan, J.-H., Agis, H., Wimazal, F., Baghestanian, M., Rezaie-Majd, A., Sperr, W. R., Lechner, K., et al. (2001) · Blood · doi:10.1182/blood.v98.8.2580 · Cited by 56 · cited 2×
“Its serum level may also be increased due to its release from basophils [35,36]; tissue injury, venous stasis, hemolysis or clotting during blood collection and sample preparation or improper centrifugation/storage; a diet rich in histamine [41].”
BackgroundValent, P., Horny, H.-P., Triggiani, M., & Arock, M. (2011) · International Archives of Allergy and Immunology · doi:10.1159/000323763 · Cited by 50 · cited 1×
“The D816V mutation is also expressed in people in whom neither criteria for SM nor for cutaneous mastocytosis (CM) are fulfilled [22,33,49,54–56] and may contribute to the symptoms of MC activation syndrome (MCAS); specifically, in MCAS cases, in which only KIT mutation is presented, they are defined as monoclonal MC…”
BackgroundHauswirth, A. W., Escribano, L., Prados, A., Nuñez, R., Mirkina, I., Kneidinger, M., Florian, S., Sonneck, K., Vales, A., Schernthaner, G.-H., et al. (2008) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463200802100404 · Cited by 48
Assays for measuring in vitro basophil activation induced by recombinant allergens
Valent, P., Hauswirth, A. W., Natter, S., Sperr, W. R., Bühring, H.-J., & Valenta, R. (2004) · Methods · doi:10.1016/j.ymeth.2003.08.006 · Cited by 46 · cited 1×
“Various assays have been proposed to document MC and basophil activation [30,31].”
BackgroundProlonged elevation of serum tryptase in idiopathic anaphylaxis
Shanmugam, G., Schwartz, L. B., & Khan, D. A. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.12.1356 · Cited by 43
Immunology and clinical manifestations of non-clonal mast cell activation syndrome
Cardet, J.-C., Castells, M. C., & Hamilton, M. J. (2013) · Current Allergy and Asthma Reports · doi:10.1007/s11882-012-0326-8 · Cited by 39 · cited 2×
“On the contrary, most adults with CM have an underlying SM and so they should undergo a BM biopsy regardless of the presence of associated systemic symptoms of mediator release [60].”
BackgroundEvaluation of mast cell activation syndromes: impact of pathology and immunohistology
Horny, H.-P., Sotlar, K., & Valent, P. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000336374 · Cited by 21 · cited 2×
“[45] have been proven as the main site for diagnosis.”
Background
Cited by
Mast cells, brain inflammation and autism
Theoharides, T. C., Stewart, J. M., Panagiotidou, S., & Melamed, I. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.086 · Cited by 138
Self-citationRastogi, V., Singh, D., Mazza, J. J., Parajuli, D., & Yale, S. H. (2018) · Clinical Medicine & Research · doi:10.3121/cmr.2017.1379a · Cited by 32
Impact of mast cells in fibromyalgia and low‐grade chronic inflammation: Can IL‐37 play a role?
Conti, P., Gallenga, C. E., Caraffa, A., Ronconi, G., & Kritas, S. K. (2020) · Dermatologic Therapy · doi:10.1111/dth.13191 · Cited by 29
Self-citation
Metadata
- Authors
- Petra, A. I., Panagiotidou, S., Stewart, J. M., Conti, P., & Theoharides, T. C.
- Venue
- Expert Review of Clinical Immunology
- Publisher
- Informa UK Limited
- Published
- 2014-05
- Volume
- 10
- Issue
- 6
- Pages
- 729-739
- ISSN
- 1744-666X (ISSN-L)
- 1744-8409
- OpenAlex
- W2134576996
- Cited by
- 54
- References
- 25
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.